Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes

Current Eye Research

Volumn 40, Issue 3, 2015, Pages 338-345

  Yasuda, Masayuki ^a   Shimura, Masahiko ^b   Kunikata, Hiroshi ^a   Kanazawa, Hiroko ^c   Yasuda, Kanako ^b   Tanaka, Yuji ^a   Konno, Hideyuki ^a   Takahashi, Mai ^a   Kokubun, Taiki ^a   Maruyama, Kazuichi ^a   Sato, Noriko ^a   Kakizaki, Masako ^a   Sato, Mari ^a   Tsuji, Ichiro ^a   Miyata, Toshio ^a   Nakazawa, Toru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^c TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Advanced glycation end products; AGE; Biomarker; Diabetic retinopathy; Skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CREATININE;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN AUTOFLUORESCENCE; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FLUORESCENCE IMAGING; METABOLISM; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN;

AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; OPTICAL IMAGING; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84925355710     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.918152     Document Type: Article

References (41)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321.
2. Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ, Shaw JE. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med 2013;30:387-398.
3. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
4. Schoenberger SD, Miller DM, Riemann CD, Foster RE, Sisk RA, Hutchins RK, et al. Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2011;42:474-480.
5. Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids 2012;42: 1205-1220.
6. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001;85:746-753.
7. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011;46:217-224.
8. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009;52: 789-797.
9. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30: 107-112.
10. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, et al. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet Med 2012;29:492-500.
11. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005;54:S97-S107.
12. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111.
13. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163.
14. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249-1257.
15. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-1068.
16. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012;16:153-166.
17. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104:103-113.
18. Gopal P, Reynaert NL, Scheijen JL, Engelen L, Schalkwijk CG, Franssen FM, et al. Plasma AGEs and skin autofluorescence are increased in COPD. Eur Respir J 2014;43:430-438.
19. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98:741-756.
20. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330.
21. Koetsier M, Nur E, Chunmao H, Lutgers HL, Links TP, Smit AJ, et al. Skin color independent assessment of aging using skin autofluorescence. Opt Express 2010;18: 14416-14429.
22. Arsov S, Trajceska L, van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, et al. Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs 2013;37:E114-E122.
23. Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: http://www.R-project.org. 2013.
24. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
25. Januszewski AS, SachithanandanN, Karschimkus C, O'Neal DN, Yeung CK, Alkatib N, et al. Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med 2012;29:726-733.
26. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986;314:403-408.
27. Chabroux S, Canoui-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 2010;36:152-157.
28. Araszkiewicz A, Naskret D, Niedzwiecki P, Samborski P, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes. Diabetes Technol Ther 2011;13:837-842.
29. Hamlin CR, Kohn RR, Luschin JH. Apparent accelerated aging of human collagen in diabetes mellitus. Diabetes 1975;24:902-904.
30. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463-2469.
31. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991;87:1910-1915.
32. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-537.
33. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994;91:5710-5714.
34. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170.
35. Matsumoto Y, Takahashi M, Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Jpn J Ophthalmol 2002;46: 406-412.
36. Yokoi M, Yamagishi SI, Takeuchi M, Ohgami K, Okamoto T, Saito W, et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005;89:673-675.
37. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end productinduced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277:20309-20315.
38. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010;51:4867-4874.
39. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, DahmsW, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-880.
40. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:4295-4301.
41. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31: 517-521.